Top Markets
Coin of the day
CellSeed Inc. CellSeed Inc.

CellSeed Inc.

7776
Classificação em ações #24575
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell... CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Preço da ação
$1.52
Valor de mercado
$59.10M
Variação (1 dia)
-0.85%
Variação (1 ano)
-51.30%
País
JP
Negociar CellSeed Inc. (7776)

Categoria

Lucros da CellSeed Inc. (7776)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da CellSeed Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da CellSeed Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
$-3.09B -
US
- -
CH